T-cell receptor gene transfer for the treatment of leukemia and other tumors.
作者信息
Heemskerk Mirjam H M
出版信息
Haematologica. 2010 Jan;95(1):15-9. doi: 10.3324/haematol.2009.016022.
Abstract
摘要
相似文献
1
T-cell receptor gene transfer for the treatment of leukemia and other tumors.用于治疗白血病和其他肿瘤的T细胞受体基因转移
Haematologica. 2010 Jan;95(1):15-9. doi: 10.3324/haematol.2009.016022.
2
Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.应用肿瘤抗原特异性T细胞受体基因转移的过继性T细胞疗法治疗人类白血病。
J Biomed Biotechnol. 2010;2010:521248. doi: 10.1155/2010/521248. Epub 2010 May 5.
3
Challenges in T cell receptor gene therapy.T 细胞受体基因治疗面临的挑战。
J Gene Med. 2012 Jun;14(6):386-99. doi: 10.1002/jgm.2637.
4
Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer.成人和脐带血T细胞可通过HA-1 T细胞受体基因转移获得HA-1特异性。
Haematologica. 2005 Oct;90(10):1415-21.
5
Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.源自中央记忆细胞而非经肿瘤特异性 TCR 基因修饰的 CD8(+)T 细胞的人类效应 T 细胞，具有用于过继免疫治疗的优越特性。
Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.
6
The Promise of Chimeric Antigen Receptor T-Cell Therapy.嵌合抗原受体T细胞疗法的前景
Oncology (Williston Park). 2016 Oct 15;30(10):880-8, 890.
7
Adoptive immunotherapy for cancer or viruses.用于癌症或病毒的过继性免疫疗法。
Annu Rev Immunol. 2014;32:189-225. doi: 10.1146/annurev-immunol-032713-120136. Epub 2014 Jan 9.
8
Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.使用改良的睡美人转座子平台，通过嵌合抗原受体修饰的淋巴细胞对急性白血病进行免疫治疗。
Oncotarget. 2016 Aug 9;7(32):51581-51597. doi: 10.18632/oncotarget.9955.
9
Prospects of chimeric antigen receptor T-cell and natural killer cell therapies in acute leukemias.嵌合抗原受体T细胞和自然杀伤细胞疗法在急性白血病中的应用前景。
Future Oncol. 2016 Oct;12(19):2179-82. doi: 10.2217/fon-2016-0125. Epub 2016 Jun 2.
10
Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma.嵌合抗原受体T细胞：消灭白血病和淋巴瘤的有力工具。
Expert Rev Hematol. 2015 Aug;8(4):383-5. doi: 10.1586/17474086.2015.1043884. Epub 2015 May 6.
引用本文的文献
1
Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy.工程化用于癌症免疫治疗的双特异性γδ T细胞受体。
Biology (Basel). 2024 Mar 20;13(3):196. doi: 10.3390/biology13030196.
2
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.比较 CAR 和 TCR 工程化 T 细胞在肿瘤细胞暴露下的性能。
Oncoimmunology. 2022 Feb 1;11(1):2033528. doi: 10.1080/2162402X.2022.2033528. eCollection 2022.
3
Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).对抗高级别胶质瘤的抗逆性：免疫治疗方法（第一部分）
Brain Sci. 2021 Mar 18;11(3):386. doi: 10.3390/brainsci11030386.
4
Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.神经肿瘤学中的过继免疫疗法：分类、最新进展和转化挑战。
Acta Biomed. 2020 Jun 30;91(7-S):18-31. doi: 10.23750/abm.v91i7-S.9952.
5
Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.基于嵌合抗原受体/受体 T 细胞的过继细胞疗法的临床转化和监管方面-德国癌症联盟的方法。
Cancer Immunol Immunother. 2018 Apr;67(4):513-523. doi: 10.1007/s00262-018-2119-y. Epub 2018 Jan 29.
6
First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?人类首例 CRISPR 基因编辑癌症临床试验：我们准备好了吗？
Curr Gene Ther. 2017;17(4):309-319. doi: 10.2174/1566523217666171121165935.
7
Clinical applications of gamma delta T cells with multivalent immunity.具有多价免疫的γδ T细胞的临床应用
Front Immunol. 2014 Dec 11;5:636. doi: 10.3389/fimmu.2014.00636. eCollection 2014.
8
Upregulated TCRζ enhances interleukin-2 production in T-cells from patients with CML.上调的 TCRζ 增强了 CML 患者 T 细胞中的白细胞介素-2 产生。
DNA Cell Biol. 2012 Nov;31(11):1628-35. doi: 10.1089/dna.2012.1798. Epub 2012 Oct 11.
9
Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer.利用功能特征鉴定用于乳腺癌、髓性白血病和前列腺癌的再定位药物。
PLoS Comput Biol. 2012 Feb;8(2):e1002347. doi: 10.1371/journal.pcbi.1002347. Epub 2012 Feb 9.
10
Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.细胞免疫疗法治疗急性髓细胞白血病的临床评估。
Cancer Immunol Immunother. 2011 Jun;60(6):757-69. doi: 10.1007/s00262-011-1022-6. Epub 2011 Apr 26.
本文引用的文献
1
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy.将人CD20作为自杀基因进行逆转录病毒转导用于过继性T细胞治疗。
Haematologica. 2009 Sep;94(9):1316-20. doi: 10.3324/haematol.2008.001677.
2
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.为临床试验开发一种 Wilms 瘤抗原特异性 T 细胞受体：工程化患者的 T 细胞可在 NOD/SCID 小鼠中消除自体白血病母细胞。
Haematologica. 2010 Jan;95(1):126-34. doi: 10.3324/haematol.2009.006486. Epub 2009 Aug 13.
3
Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.接受基因工程改造淋巴细胞的患者中缺乏特异性γ-逆转录病毒载体长末端重复启动子沉默以及淋巴细胞再刺激时的激活。
Blood. 2009 Oct 1;114(14):2888-99. doi: 10.1182/blood-2009-01-199216. Epub 2009 Jul 9.
4
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.使用人类和小鼠T细胞受体的基因疗法介导癌症消退，并靶向表达同源抗原的正常组织。
Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.
5
Preclinical development of T cell receptor gene therapy.T细胞受体基因疗法的临床前开发。
Curr Opin Immunol. 2009 Apr;21(2):209-14. doi: 10.1016/j.coi.2009.02.007. Epub 2009 Mar 25.
6
Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells.共同编程的次要组织相容性抗原反应性病毒特异性T细胞双重特异性的动力学保存
Cancer Res. 2009 Mar 1;69(5):2034-41. doi: 10.1158/0008-5472.CAN-08-2523. Epub 2009 Feb 17.
7
Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo.αβT细胞受体转移至γδT细胞可在体内产生无混合TCR二聚体的功能性效应细胞。
J Immunol. 2009 Jan 1;182(1):164-70. doi: 10.4049/jimmunol.182.1.164.
8
Resistance of mature T cells to oncogene transformation.成熟T细胞对癌基因转化的抗性。
Blood. 2008 Sep 15;112(6):2278-86. doi: 10.1182/blood-2007-12-128751. Epub 2008 Jun 19.
9
Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer.整合了CD3ζ的人T细胞受体在基因转移后诱导TCRα和β链之间形成高度优先配对。
J Immunol. 2008 Jun 1;180(11):7736-46. doi: 10.4049/jimmunol.180.11.7736.
10
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells.钙β界面的分子设计有利于人T细胞中引入的TCRαβ特异性配对。
J Immunol. 2008 Jan 1;180(1):391-401. doi: 10.4049/jimmunol.180.1.391.
Zotero 插件